Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

ASTELLAS PHARMA INC (4503)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Latest news on ASTELLAS PHARMA INC
06/15ASTELLAS PHARMA INC : Proxy Statments
CO
06/14SEATTLE GENETICS : and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Pa..
AQ
06/14ASTELLAS PHARMA : and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedoti..
AQ
06/14ASTELLAS PHARMA : Studies from Astellas Pharma Provide New Data on Diabetic Neph..
AQ
06/13PFIZER : Astellas Announces Launch of XTANDI Tablets in Japan for the Treatment ..
AQ
06/11VICAL INCORPORATED : discontinuing HSV-2 program after Phase II miss
AQ
06/11ASTELLAS PHARMA : Announces Launch of XTANDI® Tablets in Japan for the Treatment..
PU
06/07ASTELLAS PHARMA : New Findings in Medicinal Chemistry Described from Astellas Ph..
AQ
06/05ASTELLAS PHARMA : and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedoti..
AQ
06/04ASTELLAS PHARMA : Submits Application for Approval of Peficitinib for Rheumatoid..
AQ
06/04ASTELLAS PHARMA : Announces Acquisition of Own Shares
AQ
06/04ASTELLAS PHARMA : and FibroGen Announce Topline Results from Double-Blind Japan ..
AQ
06/04ASTELLAS PHARMA : and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedoti..
PU
06/01ASTELLAS PHARMA : Oncology C3 Prize Returns for Third Year with Focus on Improvi..
AQ
06/01ASTELLAS PHARMA : Announces Personnel Change
PU
06/01ASTELLAS PHARMA : Oncology C3 Prize® Returns for Third Year with Focus on Improv..
PU
05/31ASTELLAS PHARMA : "Stabilized Pharmaceutical Composition" in Patent Application ..
AQ
05/31ASTELLAS PHARMA : and FibroGen Announce Topline Results from Double-Blind Japan ..
PU
05/31ASTELLAS PHARMA : Submits Application for Approval of Peficitinib for Rheumatoid..
PU
05/31ASTELLAS PHARMA : Announces Acquisition of Own Shares
PU
05/30ASTELLAS PHARMA : U.S. FDA Grants Priority Review to Astellas` New Drug Applicat..
AQ
05/30ASTELLAS PHARMA : FDA reviewing Astellas' AML candidate
AQ
05/29ASTELLAS PHARMA : U.S. FDA Grants Priority Review to Astellas’ New Drug Ap..
PU
05/29ASTELLAS PHARMA : U.S. FDA Grants Priority Review to Astellas' New Drug Applicat..
AQ
05/25ASTELLAS PHARMA : Appoints Bernhardt Zeiher, M.D., as New Chief Medical Officer
AQ
05/25ASTELLAS PHARMA : Announces Abstracts Highlighting Growing Oncology Portfolio to..
AQ
05/25ASTELLAS PHARMA INC. : - Addition of Mirabegron to Tamsulosin Demonstrates Super..
AQ
05/25ASTELLAS PHARMA : Eurofins Expands Its Biopharmaceutical Products Testing Footpr..
AQ
05/23Astellas unveils new R&D strategy
AQ
05/22GILEAD SCIENCES : Gileads Kite adds cell therapy manufacturing capacity
AQ
05/22Dova's thrombocytopenia drug wins FDA approval
AQ
05/21ASTELLAS PHARMA : Announces Abstracts Highlighting Growing Oncology Portfolio to..
AQ
05/17ASTELLAS PHARMA : New Findings from Astellas Pharma Update Understanding of Diab..
AQ
05/17AQUINOX PHARMACEUTICALS : and Astellas Announce Exclusive Licensing Agreement fo..
AQ
05/11AQUINOX PHARMACEUTICALS : and Astellas Announce Exclusive Licensing Agreement fo..
AQ
05/11ASTELLAS PHARMA INC. : - FDA Approves Supplemental New Drug Application for Myrb..
AQ
05/10ASTELLAS PHARMA : Studies from Astellas Pharma Add New Findings in the Area of B..
AQ
05/10ASTELLAS PHARMA : Study Findings on Immunoglobulins Are Outlined in Reports from..
AQ
05/09ASTELLAS PHARMA : FDA Approves Supplemental New Drug Application for Myrbetriq (..
AQ
05/03ASTELLAS PHARMA : Submits New Drug Applications for Approval of Gilteritinib for..
AQ
05/03ASTELLAS PHARMA : Study Data from Astellas Pharma Update Knowledge of Science (C..
AQ
04/30ASTELLAS PHARMA : Announces Cancellation of Treasury Shares
AQ
04/30ASTELLAS PHARMA : Reports Financial Results for FY2017
AQ
04/30SHOWA DENKO K K : SDK Provides LED for Research on Rice-Based Oral Vaccine 'Muco..
AQ
04/26ASTELLAS PHARMA : Findings on Fibromyalgia Discussed by Investigators at Astella..
AQ
04/26ASTELLAS PHARMA : Announces Sale of Certain Agensys Research Facilities to Kite,..
AQ
04/26ASTELLAS PHARMA : Reports Financial Results for FY2017
BU
04/25CYTOKINETICS : Announces Presentation of Data From Phase 2 Clinical Study of Rel..
AQ
04/25ASTELLAS PHARMA : Submits New Drug Applications for Approval of Gilteritinib for..
AQ
04/24SHOWA DENKO K K : SDK Provides LED for Research on Rice-Based Oral Vaccine "Muco..
AQ
04/23ASTELLAS PHARMA : Announces Sale of Certain Agensys Research Facilities to Kite,..
AQ
04/21ASTELLAS PHARMA : sells certain U.S. research facilities to Gilead
AQ
04/19ASTELLAS PHARMA : Findings on Immunoglobulins Discussed by Investigators at Aste..
AQ
04/16ACTINIUM PHARMACEUTICALS : to Showcase Capabilities of its AWE Technology Platfo..
AQ
04/12ASTELLAS PHARMA : Named "Outstanding Employer" for Supporting Employees with Mil..
AQ
04/12ASTELLAS PHARMA : New Colitis Data Have Been Reported by Investigators at Astell..
AQ
04/05SEATTLE GENETICS : and Astellas Receive FDA Breakthrough Therapy Designation for..
AQ
04/05ASTELLAS PHARMA : Studies from Astellas Pharma in the Area of Nephropathy Descri..
AQ
04/03ASTELLAS PHARMA : to Participate in 'Neglected Tropical Diseases Drug Discovery ..
AQ
04/02ASTELLAS PHARMA : Announces Personnel Change
AQ
03/30ACTINIUM PHARMACEUTICALS : Announces Collaborative Research Partnership with Ast..
AQ
03/29ASTELLAS PHARMA : Patent Issued for Pharmaceutical Composition Comprising Solife..
AQ
03/29ASTELLAS PHARMA : New Findings in Lymphoma Described from Astellas Pharma phenyl..
AQ
03/29ASTELLAS PHARMA : Investigators from Astellas Pharma Have Reported New Data on C..
AQ
03/29ASTELLAS PHARMA INC. : - Notice of Completion of Acquisition of Own Shares
AQ
03/29ACTINIUM PHARMACEUTICALS : Announces Collaborative Research Partnership with Ast..
AQ
03/28ASTELLAS PHARMA INC. : - SUJANU Combination Tablets combining type-2 diabetes dr..
AQ
03/28ASTELLAS PHARMA INC : Ex-dividend day for final dividend
FA
03/27ASTELLAS PHARMA : Receives Orphan Drug Designation from the Japanese MHLW for Gi..
AQ
03/27SEATTLE GENETICS : and Astellas Receive FDA Breakthrough Therapy Designation for..
AQ
03/22ASTELLAS PHARMA : Data on Type 2 Diabetes Discussed by Researchers at Astellas P..
AQ
03/22ASTELLAS PHARMA : New Findings on Taxol Therapy from Astellas Pharma Summarized
AQ
03/22PFIZER INC. : - U.S. FDA Grants Priority Review for a Supplemental New Drug Appl..
AQ
03/21ASTELLAS PHARMA INC. : - European Medicines Agency Accepts Type II Variation App..
AQ
03/21PFIZER : & Astellas announce US FDA grants priority review status to sNDA for Xt..
AQ
1  2  3  4  5  6  7  8  9Next
Financials ( JPY)
Sales 2019 1 287 B
EBIT 2019 264 B
Net income 2019 206 B
Finance 2019 395 B
Yield 2019 2,20%
P/E ratio 2019 16,19
P/E ratio 2020 17,93
EV / Sales 2019 2,36x
EV / Sales 2020 2,34x
Capitalization 3 429 B
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 1 698  JPY
Spread / Average Target -1,9%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Chief Financial Officer
Akira Kamimura Manager-Accounting & IR Contact
Mitsunori Matsuda General Manager-Pharmaceutical Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC19.45%31 909
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 330
ROCHE HOLDING LTD.-14.81%184 168
MERCK AND COMPANY8.39%166 880